TARA - Protara Therapeutics, Inc. Quarterly EPS earnings growth
High FDA testing costs and patent protection create a stringent barrier to entry for competitors in oncology. The quarterly earnings per share growth rate reflects current dynamics, where the value of -10.10 characterizes this level. Protara Therapeutics (TARA) maintains stability through diversified production via bio-factories and the disciplined financial control of Jesse Shem's team.
%20Earnings%20per%20share%20growth%20in%20annualized%20terms%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_TARA_-_Protara-Therapeutics_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "Protara Tx (TARA): Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/14/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Protara Therapeutics
- market value and analyst target forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
Debt to Equity Protara Therapeutics|TARA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Protara Therapeutics|TARA - Company Cumulative Indebtedness|Debts to Book Capitalization Protara Tx|TARA - Company Long-Term Debts|Company Short-Term Debt Protara Therapeutics|Quick Ratio protaratx.com
- earnings and market multiples details:
TARA - Net Profit|Future Profit Protara Therapeutics|TARA - Company Value to Net Income|Projected Price to Earnings Protara|TARA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Protara Therapeutics, Inc.|TARA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Protara Therapeutics|TARA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months protaratx.com|TARA - Earnings per share increase in current year|Earnings growth forecast for next year Protara Therapeutics
- issuer revenue and sales details:
Fundamental company valuation:Protara Therapeutics Inc - TARA
Protara Therapeutics focuses on creating innovative targeted therapies to combat bladder cancer. This quarterly earnings per share chart reflects the dynamics of net income distributed per common share. This metric allows for a real-time assessment of business efficiency by comparing accounting results with market capitalization. The positive trend confirms the successful deployment of resources within orphan drug development. Stable growth of this indicator guarantees the resilience of the stock price.
Competitor analysis
ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|Aura Bio (AURA) - Quarterly EPS earnings growth|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|ARAY: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SLS (SELLAS Life Sciences Group, Inc.)|Year-over-year earnings per share growth rate for the last twelve months ACTU|Citius Oncology - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HURA|fatetherapeutics.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aadi Bioscience|TCRX: Quarterly EPS earnings growth|CSBR - Year-over-year net earnings per share change for the last twelve months|XBIT (XBiotech) - Quarterly EPS earnings growth|CVM: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth OSTX|RADX (Radiopharm Theranostics Limited) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTV (Artiva Biotherapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months ANL|VERU: Year-over-year net earnings per share growth for the last 12 months|TPST - Quarterly EPS earnings growth|XLO (xiliotx.com) - Year-over-year net earnings per share growth for the last 12 months|Renovaro Biosciences - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months MURA|Year-over-year earnings per share growth for the last twelve months KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)
